Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Concert Pharmaceuticals Inc. (CNCE)

10.25   0.43 (4.38%) 10-01 15:56
Open: 9.83 Pre. Close: 9.82
High: 10.37 Low: 9.83
Volume: 101,496 Market Cap: 304M
Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. The company is headquartered in Lexington, Massachusetts and currently employs 71 full-time employees. The firm is engaged in the discovery and development of small molecule drugs. The firm operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The firm's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The firm's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 9.958 - 10.013 10.013 - 10.058
Low: 9.293 - 9.37 9.37 - 9.432
Close: 9.704 - 9.821 9.821 - 9.916

Technical analysis

as of: 2020-10-01 3:31:57 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 13.69     One year: 15.99
Support: Support1: 9.85    Support2: 8.69
Resistance: Resistance1: 11.72    Resistance2: 13.69
Pivot: 10.08
Moving Average: MA(5): 9.63     MA(20): 9.99
MA(100): 9.81     MA(250): 9.13
MACD: MACD(12,26):     Signal(9): 0.03
Stochastic oscillator: %K(14,3): 42.74     %D(3): 30.27
RSI: RSI(14): 54.74
52-week: High: 13.09  Low: 5.47  Change(%): 77.1
Average Vol(K): 3-Month: 11861  10-Days: 17849

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
CNCE has closed below upper band by 39.3%. Bollinger Bands are 7.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 01 Oct 2020
Molina Acquires Affinity, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha

Thu, 01 Oct 2020
Concert Pharmaceuticals (NASDAQ:CNCE) Upgraded at BidaskClub - MarketBeat

Tue, 29 Sep 2020
Concert Pharmaceuticals Completes Enrollment in CTP-692 Phase 2 Trial in Patients with Schizophrenia - Business Wire

Thu, 24 Sep 2020
How Does Concert Pharmaceuticals Inc (CNCE) Stock Rank on Wall Street? - InvestorsObserver

Fri, 18 Sep 2020
Should You Buy Concert Pharmaceuticals Inc (CNCE) Stock After it Has Risen 14.79% in a Week? - InvestorsObserver

Mon, 14 Sep 2020
Mizuho Reaffirms "Buy" Rating for Concert Pharmaceuticals (NASDAQ:CNCE) - MarketBeat

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 30
Shares Float (M) 23
% Held by Insiders 9.15
% Held by Institutions 59.46
Shares Short (K) 762
Shares Short P. Month (K) 758

Stock Financials

EPS -2.630
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 4.860
Profit Margin
Operating Margin -1106.11
Return on Assets (ttm) -26.2
Return on Equity (ttm) -51.2
Qtrly Rev. Growth 12934.7
Gross Profit (p.s.) -1.979
Sales Per Share 0.216
EBITDA (p.s.) -2.337
Qtrly Earnings Growth
Operating Cash Flow (M) -63
Levered Free Cash Flow (M) -35

Stock Valuations

PE Ratio -3.91
PEG Ratio
Price to Book value 2.12
Price to Sales 47.57
Price to Cash Flow -4.83

Stock Dividends

Dividend
Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2020 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.